Blood-loss and critical illness drug startup gets $2.9 million on path to human studies
A startup to stop hemorrhagic shock and treat cardiac and other critical illnesses has a new infusion of capital on its road to the first tests in humans.
Perfusion Medical this fall was awarded a $2.9 million grant from the Defense Health Agency. The Small Business Innovation Research (SBIR) funding will enable the company to complete pre-clinical studies and submit an Investigational New Drug (IND) application to the FDA for its drug candidate, called PM-208 (developed under the name PEG-20k). The solution was invented by a team led by Martin J. Mangino, Ph.D., a professor of surgery, physiology and biophysics in the Department of Surgery at the VCU School of Medicine.
Find more about Perfusion Medical, see this January 2023 story in the Richmond Times-Dispatch